NasdaqCM · Biotechnology

Avalo Therapeutics (AVTX)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+122.7%

$44.15 average target

$19.83+0.01 (+0.1%)Latest market snapshot · Yahoo Finance

Market cap$1.06B

Cash$400.3M

Quarterly burn$20.0M

Pipeline assets10

Short float24.5%

Market expectations

Analyst Ratings & Price Targets

Data may be delayed

Street view at a glance

The average target implies 122.7% upsideTargets are estimates—not guarantees—and can change after company updates.

$44.15Average target

Wall Street consensus

Strong BuyBased on 13 analyst opinions

15ratings

Buy 15Hold 0Sell 0

Price-target range

$44.15

+122.7%

Low $30.00High $60.00

CurrentAverage

Bear case$30.00+51.3%

Base case$44.15+122.7%

Bull case$60.00+202.6%

Analyst coverage13published opinions

Bullish share100%buy recommendations

Target spread$30low-to-high dispersion

Consensus score1.11.0 is strongest

Recommendation mix

Current rating breakdown

15 tracked ratings

Company profile

About Avalo Therapeutics

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.